Insider Trading Alert - MXIM, CVD And NOC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 26, 2014, 172 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $41.00 to $204,930,000.00.

Highlighted Stocks Traded by Insiders:

Maxim Integrated Products (MXIM) - FREE Research Report

Doluca Tunc who is President, Ceo & Director at Maxim Integrated Products sold 12,000 shares at $32.00 on Feb. 26, 2014. Following this transaction, the President, Ceo & Director owned 1.1 million shares meaning that the stake was reduced by 1.03% with the 12,000-share transaction.

The shares most recently traded at $32.14, up $0.14, or 0.44% since the insider transaction. Historical insider transactions for Maxim Integrated Products go as follows:

  • 4-Week # shares sold: 9,232
  • 12-Week # shares sold: 29,398
  • 24-Week # shares sold: 34,398

The average volume for Maxim Integrated Products has been 3.2 million shares per day over the past 30 days. Maxim Integrated Products has a market cap of $9.0 billion and is part of the technology sector and electronics industry. Shares are up 14.23% year-to-date as of the close of trading on Wednesday.

Maxim Integrated Products, Inc. designs, develops, manufactures, and markets various linear and mixed-signal integrated circuits worldwide. The company also provides a range of high-frequency process technologies and capabilities for use in custom designs. The stock currently has a dividend yield of 3.26%. The company has a P/E ratio of 23.8. Currently there are 8 analysts that rate Maxim Integrated Products a buy, no analysts rate it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MXIM - FREE

TheStreet Quant Ratings rates Maxim Integrated Products as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Maxim Integrated Products Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Covance (CVD) - FREE Research Report

Nutt Brian H. who is Principal Accounting Officer at Covance sold 210 shares at $103.22 on Feb. 26, 2014. Following this transaction, the Principal Accounting Officer owned 1,655 shares meaning that the stake was reduced by 11.26% with the 210-share transaction.

The shares most recently traded at $103.62, up $0.40, or 0.39% since the insider transaction. Historical insider transactions for Covance go as follows:

  • 4-Week # shares sold: 37,296
  • 12-Week # shares sold: 37,296
  • 24-Week # shares bought: 200
  • 24-Week # shares sold: 47,461

The average volume for Covance has been 475,500 shares per day over the past 30 days. Covance has a market cap of $5.8 billion and is part of the health care sector and health services industry. Shares are up 17.44% year-to-date as of the close of trading on Wednesday.

Covance Inc., a drug development services company, provides various early-stage and late-stage product development services primarily to the pharmaceutical, biotechnology, and medical device industries primarily in the United States and Europe. The company has a P/E ratio of 32.7. Currently there are 7 analysts that rate Covance a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVD - FREE

TheStreet Quant Ratings rates Covance as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Covance Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Northrop Grumman (NOC) - FREE Research Report

Flach Gloria A who is Corp. VP & Pres Electronic Sys at Northrop Grumman sold 5,997 shares at $120.88 on Feb. 26, 2014. Following this transaction, the Corp. VP & Pres Electronic Sys owned 11,937 shares meaning that the stake was reduced by 33.44% with the 5,997-share transaction.

The shares most recently traded at $118.80, down $2.08, or 1.75% since the insider transaction. Historical insider transactions for Northrop Grumman go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 63,057
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 63,057
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 92,760

The average volume for Northrop Grumman has been 1.5 million shares per day over the past 30 days. Northrop Grumman has a market cap of $25.9 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are up 3.59% year-to-date as of the close of trading on Wednesday.

Northrop Grumman Corporation provides systems, products, and solutions in aerospace, electronics, information systems, and technical service areas to government and commercial customers worldwide. The stock currently has a dividend yield of 2.04%. The company has a P/E ratio of 14.3. Currently there are 2 analysts that rate Northrop Grumman a buy, no analysts rate it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NOC - FREE

TheStreet Quant Ratings rates Northrop Grumman as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Northrop Grumman Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Dow Futures Plunge, Global Markets Rocked as Trump Takes Trade War to Next Level

Dow Futures Plunge, Global Markets Rocked as Trump Takes Trade War to Next Level

Trump Issues New Trade Threats, Apple, ZTE, GameStop - 5 Things You Must Know

Trump Issues New Trade Threats, Apple, ZTE, GameStop - 5 Things You Must Know

China-Focused Stocks Hit Hard as Beijing Responds to Trump Tariff Threats

China-Focused Stocks Hit Hard as Beijing Responds to Trump Tariff Threats

Asia Markets Fall on Latest Tariff Threats From Trump

Asia Markets Fall on Latest Tariff Threats From Trump

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI